

Substitute for form 1449A/PTO		NOV 18 2004		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number		10/801,729	
		Filing Date		March 15, 2004	
		First Named Inventor		KAO, PETER N.	
		Art Unit		1614	
		Examiner Name			
Sheet	1	of	2	Attorney Docket Number	STAN-352

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
BK		US- 5,968,983	October 19, 1999	Kaesemeyer		
		US- 6,147,109	November 14, 2000	Liao, et al.		
		US- 6,425,881	July 30, 2002	Kaesemeyer		
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
OTHER ART—NON PATENT LITERATURE DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T ²
		BERGER, R, et al., ALTERED ARTERIAL EXPRESION PATTERNS OF INDUCIBLE AND ENDOTHELIAL NITRIC OXIDE SYNTHASE IN PULMONARY PLEXOGENIC ARTERIOPATHY CASUED BY CONGENITAL HEART DISEASE, (2001), Am. J. Respir. Crit. Care Med., 163:1493-1499				
		BUSTOS, C. et al., HMG-COA REDUCTASE INHIBITION BY ATORVASTATIN REDUCES NEOINTIMAL INFLAMMATION IN A RABBIT MODEL OF ATHEROSCLEROSIS, (1998), J. Am. Coll. Cardiol., 32:2057-2064				
		DENG, Z. et al., FAMILIAL PRIMARY PULMONARY HYPERTENSION (GENE PPH1) IS CAUSED BY MUTATIONS IN THE BONE MORPHOGENETIC PROTEIN RECEPTOR-II GENE, (2000), Am. J. Hum. Genet., 67:737-744				
		INDOLFI, C. et al., EFFECTS OF HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR SIMVASTATIN ON SMOOTH MUSCLE CELL PROLIFERATION IN VITRO AND NEOINTIMAL FORMATION IN VIVO AFTER VASCULAR INJURY, (2000), J. Am. Coll. Cardiol., 35: 214-221				
✓		KOBASHIGAWA, J.A. et al., EFFECT OF PRAVASTATIN ON OUTCOMES AFTER CARDIAC TRANSPLANTATION, (1995), N. Engl. J. Med., 333:621-627				

Examiner Signature	/Brian-Yong Kwon/	Date Considered	11/10/2006
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/801,729	
			Filing Date	March 15, 2004	
			First Named Inventor	KAO, PETER N.	
			Group Art Unit	1614	
Sheet	2	of	2	Examiner Name	
				Attorney Docket Number	STAN-352

OTHER ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
BK		KOH, K.K., EFFECTS OF STATINS ON VASCULAR WALL: VASOMOTOR FUNCTION, INFLAMMATION, AND PLAQUE STABILITY, (2000), Cardiovascular Res., 47: 648-657	
		KWAK, B. et al., STATINS AS A NEWLY RECOGNIZED TYPE OF IMMUNOMODULATOR, (2000), Nat. Med., 6:1399-402	
		LAUFS, U. et al., INHIBITION OF 3-HYDOXY-3-METHYLGLUTARYL (HMG)-COA REDUCTASE BLOCKS HYPOXIA-MEDIATED DOWN-REGULATION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE, (1997), J. Biol. Chem., 272: 31725-31729	
		LAUFS, U. et al., 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITORS ATTENUATE VASCULAR SMOOTH MUSCLE PROLIFERATION BY PREVENTING RHO GTPASE-INDUCED DOWN-REGULATION OF P27 ^{KIP1} , (1999), J. Biol. Chem., 274: 21926-21931	
		MACHADO, R.D. et al., BMPR2 HAPLOINSUFFICIENCY AS THE INHERITED MOLECULAR MECHANISM FOR PRIMARY PULMONARY HYPERTENSION, (2000), Am. J. Hum. Genet., 68:92-102	
		MARON, D.J., et al., CURRENT PERSPECTIVES ON STATINS, (2000), Circulation, 101:207-13	
		NEWMAN, J.H., et al., MUTATION IN THE GENE FOR BONE MORPHOGENETIC PROTEIN RECEPTOR II AS A CAUSE OF PRIMARY PULMONARY HYPERTENSION IN A LARGE KINDRED, (2001), New Engl. J. Med., 345:319-324	
↓		WEITZ-SCHMIDT, G. et al., STATINS SELECTIVELY INHIBIT LEUKOCYTE FUNCTION ANTIGEN-1 BY BINDING TO A NOVEL REGULATORY INTEGRIN SITE, (2001), Nat. Med., 7:687-92	

Examiner Signature	/Brian-Yong Kwon/	Date Considered	11/10/2006
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.